Rosiglitazone

Generic Name: Rosiglitazone

Brand Names: Avandamet, Avandia

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₁₉N_₃O_₃S

CAS Number: 122320-73-4

Unique Ingredient Identifier: 05V02F2KDG

Background: Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl). Like other thiazolidinediones, the mechanism of action of rosiglitazone is by activation of the intracellula...

Indication: Rosiglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Associated Conditions: Type 2 Diabetes Mellitus

Associated Therapies: -

Clinical Trials

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

Phase 2

Recruiting

Conditions: Melanoma
HNSCC
NSCLC
Hepatocellular Carcinoma
Urothelial Cancer
Gastric Adenocarcinoma
Esophageal Adenocarcinoma
Microsatellite Instability-High Solid Malignant Tumor

Interventions: Drug: Nivolumab or Pembrolizumab (dependent upon approved indication)
Drug: Metformin
Drug: Rosiglitazone

First Posted Date: 2019-10-03

Last Posted Date: 2024-02-07

Lead Sponsor: Dan Zandberg

Target Recruit Count: 72

Registration Number: NCT04114136

Locations: 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

A Pilot Study of Rosiglitazone in the Treatment of GH Secreting Pituitary Adenomas

Not Applicable

Conditions: Pituitary Tumor

Interventions: Drug: Rosiglitazone

First Posted Date: 2017-10-13

Last Posted Date: 2017-10-13

Lead Sponsor: Zhaoyun Zhang

Target Recruit Count: 24

Registration Number: NCT03309319

Locations: 🇨🇳
Huashan Hospital, Shanghai, Shanghai, China

Rosiglitazone Adjunctive Therapy for Severe Malaria in Children

Not Applicable

Completed

Conditions: Malaria

Interventions: Drug: Placebo
Drug: Rosiglitazone

First Posted Date: 2016-03-01

Last Posted Date: 2024-02-21

Lead Sponsor: Centro de Investigacao em Saude de Manhica

Target Recruit Count: 210

Registration Number: NCT02694874

Locations: 🇲🇿
Centro de Investigação em Saude da Manhiça, Manhiça, Maputo, Mozambique

Effects of Rosiglitazone and Metformin on Metabolism in Type 2 Diabetes

Phase 4

Completed

Conditions: Type 2 Diabetes
Insulin Sensitivity

Interventions: Drug: Placebo
Drug: Metformin
Drug: Rosiglitazone

First Posted Date: 2015-08-18

Last Posted Date: 2015-08-18

Lead Sponsor: Turku University Hospital

Target Recruit Count: 48

Registration Number: NCT02526615

Locations: 🇫🇮
Turku PET Centre, Turku, Finland
🇫🇮
Turku university hospital, PET center, Turku, Finland
🇫🇮
Turku PET Centre (Turku University Hospital), Turku, Finland

Identification of Null Allelic Variant of CYP2C8 In A Korean Population

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Rosiglitazone
Genetic: CYP2C8 genotype

First Posted Date: 2013-06-07

Last Posted Date: 2013-06-07

Lead Sponsor: Inje University

Target Recruit Count: 11

Registration Number: NCT01872780

Compare the Pharmacokinetics of Omeprazole, Rosiglitazone, and Desipramine When Administered With Avanafil in Healthy Male Subjects

Phase 1

Completed

Conditions: Erectile Dysfunction

Interventions: Drug: Rosiglitazone
Drug: Omeprazole
Drug: Desipramine

First Posted Date: 2011-08-11

Last Posted Date: 2011-08-11

Lead Sponsor: VIVUS LLC

Target Recruit Count: 60

Registration Number: NCT01415128

Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH

Phase 4

Terminated

Conditions: NASH (Non-alcoholic Steato-hepatitis)

Interventions: Drug: Rosiglitazone
Drug: alpha-lipoic acid
Drug: Rosiglitazone/alpha-lipoic acid

First Posted Date: 2011-08-01

Last Posted Date: 2011-08-19

Lead Sponsor: Seoul St. Mary's Hospital

Target Recruit Count: 26

Registration Number: NCT01406704

A Study to Assess the Effect Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Tasimelteon
Drug: Rosiglitazone
Drug: Midazolam

First Posted Date: 2011-07-26

Last Posted Date: 2014-02-17

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT01402076

Locations: 🇺🇸
Bio-Kinetic Clinical Applications, Springfield, Missouri, United States

BAY73-4506 Probe Substrate Study

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Regorafenib (Stivarga, BAY73-4506)
Drug: Warfarin
Drug: Rosiglitazone
Drug: Omeprazole
Drug: Midazolam

First Posted Date: 2011-02-01

Last Posted Date: 2019-07-10

Lead Sponsor: Bayer

Target Recruit Count: 41

Registration Number: NCT01287598

Locations: 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦
Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada
🇨🇦
British Columbia Cancer Agency-Vancouver Centre, Vancouver, British Columbia, Canada

and more 1 locations

A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

Phase 1

Completed

Conditions: Solid Cancers

Interventions: Drug: Vismodegib
Drug: Norethindrone/ethinyl estradiol
Drug: Rosiglitazone

First Posted Date: 2010-09-27

Last Posted Date: 2015-06-29

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 52

Registration Number: NCT01209143

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy